Product Description
Mechanisms of Action: PGF Agonist,GPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Vaginal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Belgium | Bulgaria | Canada | Colombia | Czech | Denmark | Greece | Hong Kong | India | Luxembourg | Malaysia | Malta | New Zealand | Peru | Philippines | Serbia | Singapore | Slovakia | Slovenia | Sri Lanka | Sweden | Taiwan | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|